Indapamide pharma grade API is the sulfamoyl-benzamide derivative 4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide, CAS 26807-65-8, molecular formula C16H16ClN3O3S, and relative molecular mass 365.83 g/mol. The bulk substance is a white or almost white crystalline powder supplied for further pharmaceutical manufacture into tablets, capsules, granules, and oral or injectable dosage forms where regional prescribing and licensing frameworks permit. Product models are differentiated by physical and microbiological quality: the standard oral solid grade is controlled for particle-size distribution, and the reduced-endotoxin injectable grade is controlled for bacterial endotoxins and particulate burden. Typical release acceptance for assay is 98.5% to 101.0% on the anhydrous basis. Oral solid grades are used in immediate-release tablets and capsules for management of essential hypertension and sodium-retentive oedema; the injectable grade is used in investigational or hospital-compounded parenteral preparations where a justified formulation and stability report exists. The low unit strengths, commonly 1.25 mg and 2.5 mg, impose strict blending and content uniformity requirements during downstream processing.

What Pharmacopoeial Monographs and Impurity Limits Apply to Bulk Indapamide?

Release and stability testing follows current Ph. Eur., USP, BP, and JP monographs. Identification is confirmed by infrared absorption spectrophotometry against a reference standard using Ph. Eur. 2.2.24 or USP <197>. HPLC assay and related-substances testing are performed on a reversed-phase C18 column with ultraviolet detection at 240 nm; typical acceptance criteria limit total related substances to ≤ 0.50%, individual unspecified impurities to ≤ 0.10%, and any specified impurity above the identification threshold to ≤ 0.10% unless otherwise justified by the pharmacopoeial monograph. Loss on drying is limited to ≤ 0.50% by USP <731>, sulfated ash to ≤ 0.10% by Ph. Eur. 2.4.14, and residual solvents are controlled according to USP <467> and Ph. Eur. 5.4. Heavy metals are tested by USP <231> or equivalent Ph. Eur. 2.4.8 where existing regional filings require. The table below summarizes route-specific release requirements for oral solid and injectable supply.

Processing of indapamide for tablets and capsules is governed by the low mass fraction of the drug substance. For a 2.5 mg dose in a 100 mg tablet core, the API represents 2.5% w/w, requiring geometric dilution or trituration with a carrier such as lactose monohydrate or microcrystalline cellulose at ratios between 1:5 and 1:10 before final blending in production-scale V-blenders or bin blenders. Blend uniformity samples are taken from 10 locations in the bin blender after 10–20 min at 15–25 rpm; relative standard deviation RSD ≤ 5.0% is commonly targeted before compression. Lubrication with magnesium stearate at 0.5–1.0% w/w is added last; extended blending beyond 5 min at high shear can coat API particles and delay dissolution. Content uniformity is assessed by USP <905>, with acceptance value AV ≤ 15 for 10 dosage units. Direct compression requires spray-dried lactose or silicified microcrystalline cellulose; wet granulation is selected when the formulation contains moisture-sensitive excipients or when flow from low-density blends is inadequate for high-speed tablet compression above 60,000 tablets/hour.

When Direct Compression Replaces Wet Granulation for Low-Dose Indapamide Tablets

The choice between direct compression and wet granulation changes the required API particle properties. Direct compression demands a tightly controlled particle-size distribution because larger agglomerates reduce content uniformity; typical API specifications for direct-compression indapamide include D90 ≤ 50 µm and D50 ≤ 20 µm by laser diffraction according to USP <429> or Ph. Eur. 2.9.31. Wet granulation is more tolerant of larger particles but exposes the drug to aqueous binder solutions. Compression force ranges between 8 kN and 15 kN on a rotary tablet press with 10 mm round flat-faced bevel-edge tooling; precompression force is set at 2–4 kN to prevent capping. Indapamide is practically insoluble in water, so dissolution from the finished tablet is controlled by deagglomeration and particle wetting rather than by solubility-limited absorption; dissolution testing uses USP Apparatus 2 at 50 rpm in a surfactant-containing medium such as 0.1 M hydrochloric acid with 0.1% sodium lauryl sulfate, or an equivalent justified by the development report. The reported melting range of indapamide is approximately 160–162 °C, above normal granulation drying conditions, but fluid-bed dryer inlet air should not exceed 60 °C when starch-based binders are present to prevent case hardening. Pre-drying of hygroscopic binders is required when ambient relative humidity exceeds 60%. Tablet hardness for immediate-release formulations is typically set between 40 N and 80 N to balance disintegration and friability; disintegration is tested by USP <701> and friability by USP <1216>.

For capsule filling, low-dose indapamide requires trituration with lactose monohydrate or pregelatinized starch to improve bulk density and flow. Capsule blends typically target bulk density 0.55–0.65 g/mL and tapped density 0.70–0.80 g/mL to ensure consistent fill weight on dosator or tamping-pin machines; capsule fill weight uniformity is assessed by Ph. Eur. 2.9.5 and content uniformity by USP <905>. Granule formulations for sachets require particle-size distribution between 150 µm and 850 µm to avoid segregation during packaging. Wet granulation using 2–4% polyvinylpyrrolidone solution as a binder at a spray rate of 5–10 g/min in a fluid-bed processor produces granules with acceptable compressibility; drying is continued until loss on drying is below 2.0%. Dry granulation by roller compaction may avoid moisture exposure but requires a minimum ribbon density of 1.05–1.15 g/cm³ to produce granules with sufficient compactability.

Long-term stability of indapamide bulk is evaluated under ICH Q1A conditions of 25 °C/60% RH and accelerated conditions of 40 °C/75% RH in sealed double polyethylene bags inside fiber drums. The API is not hygroscopic according to dynamic vapor sorption data, but moisture-impermeable packaging is used to limit surface adsorption and particle agglomeration during storage. Forced degradation studies under acidic, alkaline, oxidative, and photolytic conditions should be conducted as part of the control strategy; published data for this specific configuration is limited. Photostability is assessed by ICH Q1B, and the API should be protected from light. Retain samples are held for ≥ 1 year after the last distribution date in compliance with regional GMP. The recommended storage statement is store in a cool, dry place protected from light at 15–25 °C.

Injectable-Grade API, Endotoxin Control, and Solubility Constraints

Development of injectable presentations requires the reduced-endotoxin grade. Because indapamide is practically insoluble in water, simple aqueous solutions cannot reach therapeutic concentrations without pH adjustment or co-solvent addition. Solubility is reported below 0.1 mg/mL in water at 25 °C; formulations may use ethanol, propylene glycol, or cyclodextrin complexation, but each excipient must be justified for parenteral safety. Solution pH in parenteral prototypes is adjusted to 3.0–5.0 where solubility permits, but precipitation risk at physiological pH must be evaluated by dilution in isotonic media. The API for injectable use is subjected to additional controls for bacterial endotoxins by USP <85> and Ph. Eur. 2.6.14, with acceptance limits derived from the maximum intended dose and final product volume. Particulate matter in the finished injection is controlled by USP <788> or Ph. Eur. 2.9.19; subvisible particle counts for containers greater than 100 mL must meet ≤ 25 particles/mL at 10 µm and ≤ 3 particles/mL at 25 µm unless the product is a suspension. Sterility is confirmed by membrane filtration according to USP <71>. Aseptic processing lines require environmental monitoring to ISO 14644-1 Class 5 or better, and filter validation with a minimum 0.22 µm membrane is standard. Aqueous pre-mixes should not be held longer than 24 h without preservative because microbial proliferation risk increases; indapamide itself has no preservative activity. Published clinical data for an approved injectable indapamide finished product is limited, so formulation and stability data must be generated under the relevant current good manufacturing practice framework.

Compared with hydrochlorothiazide, indapamide is a thiazide-like sulfonamide diuretic with a longer elimination half-life and a different metabolic profile. Hydrochlorothiazide is typically administered at 12.5–25 mg once daily, whereas indapamide is effective at 1.25–2.5 mg once daily because of greater receptor affinity and higher lipid solubility. Indapamide is more extensively metabolized in the liver; approximately 5–7% of an oral dose is excreted unchanged in urine, while hydrochlorothiazide is predominantly excreted unchanged by the kidney. This difference matters for dose adjustment in renal impairment. Indapamide has been associated with less pronounced effects on serum uric acid and glucose than thiazide-type diuretics in some comparative studies, but hypokalemia remains a shared class effect at higher doses. Fixed-dose combinations with ACE inhibitors or angiotensin receptor blockers use indapamide for its longer duration and low-dose strength. Differences from chlorthalidone include a shorter half-life than chlorthalidone but greater antihypertensive potency per milligram. No direct chemical incompatibility exists with common tablet fillers, but strong oxidizing agents should be avoided during cleaning validation.